Here are the notes I made during the meeting. At least one other poster was there, and can back up, and/or dispute my interpretations.
NNVC shareholder meeting notes:
About 30 people in attendance not including board members and staff in a small meeting room.
Dr. Seymour will give a presentation at Stanford University and will also be interviewed by Bloomberg on Monday, January 26.
The larger animals used in the tox study will be beagles. Dr. Seymour says the beagles will not be harmed.
The bulk of the questions were focused on EbolaCide vs FluCide strategies.
For continued tox studies with beagles, 2.5 kg batches are required. It will take 6-9 months for results after sending the material. As a result, we are looking at Australia trials in the first part of 2016.
The bottleneck for tox studies is the ability to produce enough material for the beagles, and getting FluCide into humans is dependent upon tox studies. EbolaCide can slow down the process, but worth the gamble because it is the fastest way to get Cides into humans.
The slow part of scale-up is the lack of knowledgeable people to be able to make the product. People in big pharma have the knowledge but there needs to be borad acceptance of this technology to bring these people over.
The Shelton facility is fully capable of producing enough EbolaCide for the current Ebola crisis.
Optimistic timetable for Ebola:
Given that it has already been shipped to USAMRIID and Senator Blumenthal is on it, it will be a two-week process to cull the samples down to the best four or so.
The small animal testing is a one-month study, but we will know results in a shorter period of time.
The best-case scenario (which never happens) would be small animal testing by mid February.
The emergency nature of Ebola will allow a lots of protocol to be waived. Success will bring lots of $$.
The positives are that NNVC is helping thwart a crisis and demonstrating a rapid response to that crisis.
One of the attendees mentioned that Ebola is the low hanging fruit due to the need for governments to stockpile EbolaCide if it works, thus resulting in a revenue stream. There was no objection from the board regarding that comment. In fact, Dr. Diwan mentioned stockpiling in his later presentation.
Shelton facility: It will take three months to get up and running fully. They had ad to use the old facility to make the Ebola candidates and are now in the process of moving stuff over to the new facility. They will keep the old New Haven facility for R&D. Even during the move, they have the capability to continue to make Cides for further Ebola testing and even develop enough EbolaCide to meet human need.
Dr. Boniuk envisions building large-scale plants (including training facilities) in Texas where taxes are business friendly, land is cheap, and the cost of living is low.
